Eloralintide
Long-acting selective amylin receptor agonist in development for weight management
Clinical Research Score: 4/5 — An Eli Lilly amylin-receptor agonist backed by genuine Phase 1 and 48-week Phase 2 randomized controlled trials (published in The Lancet, 2025); promising but still investigational and not yet approved.
Categories: Weight Loss / Metabolic
What is Eloralintide?
Eloralintide is one of the newest entries in the amylin family of weight-management compounds — the same hormone pathway as cagrilintide, but designed to be more selective. Amylin is a hormone your pancreas releases alongside insulin after you eat, and its job is to tell your brain "that's enough, the meal is handled." Eloralintide mimics that signal and keeps it switched on for a full week from a single injection.
What makes eloralintide interesting is the focus on selectivity. Earlier amylin compounds activate a couple of related receptors at once, which can add side effects. Eloralintide is engineered to hit the amylin receptors specifically, with the goal of delivering strong, comfortable appetite control and less nausea. Early reports describe a natural sense of fullness, quieter cravings, and less between-meal snacking.
Because it works through a different pathway than the GLP-1 medications, eloralintide is also being explored as a partner to drugs like tirzepatide — the idea being that combining amylin and incretin signals suppresses appetite from two complementary directions. It's still investigational and early in its development, so real-world feedback is limited, but it represents the next generation of amylin-based metabolic therapy.
How Eloralintide works
Eloralintide selectively activates the amylin receptors (AMY1, AMY2, AMY3) concentrated in the area postrema of the brainstem and the hypothalamus — the brain regions that govern satiety and food intake. Activating these receptors slows gastric emptying (so food stays in the stomach longer and fullness lasts), suppresses the post-meal glucagon surge, and sends sustained satiety signals to the brain. The emphasis on receptor selectivity is intended to preserve the appetite-suppressing benefits while minimizing the off-target effects of less selective amylin analogs, and its long-acting design provides continuous appetite control from a single weekly dose.
Scientific overview
Eloralintide (LY3841136) is a long-acting, selective amylin receptor agonist developed by Eli Lilly. Unlike older amylin analogs that also bind calcitonin receptors, eloralintide is engineered for selective activation of the amylin receptors (AMY1-3), which is intended to deliver appetite suppression and satiety with a cleaner tolerability profile. Its long half-life supports once-weekly subcutaneous dosing, and it is being studied both as a standalone agent and in combination with incretin-based therapies such as tirzepatide for obesity and metabolic disease.
Dosing
- Starting dose: Low dose, titrated weekly (investigational)
- Common dosage range: Titrated weekly; clinical dosing still being established
- Administration: Subcutaneous
- Half-life: Long-acting (~once-weekly)
- Frequency: Once weekly